Remibrutinib treatment has no clinical impact on mean blood cell counts in patients with chronic spontaneous urticaria: Pooled safety analysis from REMIX-1 and REMIX-2 studies

- G. Mosnaim, H. Windom, G. Xinghua, M. Metz, S. Saini, A. Fukunaga, A. Burciu,
- S. Huang, K. Lheritier, H. Zouater, S. Haemmerle, A.G-Arnau

Please click <u>HERE</u> to subscribe to news alerts of the Novartis Urticaria Knowledge Center and to receive an email notification once the publication is available

Or use this <u>LINK</u> to access the abstract after February 28, 2025, once it is available at the congress website

AAAAI/WAO Joint Congress 2025, American Academy of Allergy, Asthma & Immunology (AAAAI) and World Allergy Organization (WAO), February 28 — March 3, 2025